Answers are grounded in this paper and cite their sources.
DrotAA did not significantly reduce mortality at 28 or 90 days, as compared with placebo, in patients with septic shock. (Funded by Eli Lilly; PROWESS-SHOCK ClinicalTrials.gov number, NCT00604214.).
No takes yet. Share an insight, caveat, or question.
Ranieri et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: